Special Use - Results Surveillance on Long-term Use With Wegovy®

Korábbi kezelés

• Previous participation in this study. Participation is defined as having given informed consent in this study
• Treatment with any investigational drug within 30 days prior to baseline (Visit 1)
• Diabetic ketoacidosis, diabetic coma, pre-coma or type 1 diabetes mellitus [The treatment with insulin is mandatory. It is not appropriate to use this drug]

Más betegség

• A history of hypersensitivity to any ingredients of this drug

Laborértékek

• In emergency cases such as severe infections and surgery in patients with type 2 diabetes [It is desirable to control blood glucose with insulin; therefore, administration of this drug is not appropriate]

Egyéb

• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
• Pregnant or possibly pregnant female
• Female who plans to become pregnant within 2 months

• Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)
• The decision to initiate treatment with commercially available Wegovy® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study
• Male or female, no age limitation
• Diagnosis of obesity disease; with either hypertension, dyslipidaemia or type 2 diabetes, insufficiently controlled with diet and exercise therapies, and should meet either of:
  • Body mass index (BMI)* greater than or equal to 27 kilograms per meter square (kg/m\^2) with two or more obesity-related comorbidities**, or
  • BMI* greater than or equal to 35 kg/m\^2
• Participant who has never been exposed to Semaglutide or who started treatment with Wegovy® within the past 4 weeks at registration
  • BMI calculation will be based on height and body weight recorded in the enrolment form of electronic case report form (eCRF) at enrolment.
  • Definition of obesity-related comorbidities are in accordance with Japan Student Services Organization (JASSO) guideline 3: (1) impaired glucose tolerance, (2) dyslipidaemia, (3) hypertension, (4) hyper-uricemia/gout, (5) coronary artery disease, (6) cerebral infarction, (7) non-alcoholic fatty liver disease, (8) menstrual disorder/infertility, (9) obstructive sleep apnoea syndrome/obesity-hypoventilation syndrome, (10) locomotory disease or (11) obesity-related kidney disease.